Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Lexaria Bioscience (LEXX) over the last 15 years, with Q4 2025 value amounting to -$280314.0.

  • Lexaria Bioscience's Change in Receivables fell 35713.58% to -$280314.0 in Q4 2025 from the same period last year, while for Nov 2025 it was -$175447.0, marking a year-over-year increase of 3341.16%. This contributed to the annual value of $213881.0 for FY2025, which is 50161.74% up from last year.
  • According to the latest figures from Q4 2025, Lexaria Bioscience's Change in Receivables is -$280314.0, which was down 35713.58% from $10229.0 recorded in Q3 2025.
  • In the past 5 years, Lexaria Bioscience's Change in Receivables ranged from a high of $408045.0 in Q4 2023 and a low of -$280314.0 during Q4 2025
  • In the last 5 years, Lexaria Bioscience's Change in Receivables had a median value of $6595.0 in 2023 and averaged -$7704.4.
  • In the last 5 years, Lexaria Bioscience's Change in Receivables soared by 138286.76% in 2021 and then tumbled by 166055.39% in 2024.
  • Over the past 5 years, Lexaria Bioscience's Change in Receivables (Quarter) stood at $119111.0 in 2021, then dropped by 29.03% to $84538.0 in 2022, then skyrocketed by 382.68% to $408045.0 in 2023, then plummeted by 73.28% to $109014.0 in 2024, then tumbled by 357.14% to -$280314.0 in 2025.
  • Its Change in Receivables was -$280314.0 in Q4 2025, compared to $10229.0 in Q3 2025 and $26964.0 in Q2 2025.